



(12) **EUROPEAN PATENT APPLICATION**

(43) Date of publication:
21.05.2003 Bulletin 2003/21

(51) Int Cl.7: **C12Q 1/68**

(21) Application number: **02257873.6**

(22) Date of filing: **14.11.2002**

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
IE IT LI LU MC NL PT SE SK TR
Designated Extension States:
AL LT LV MK RO SI

(30) Priority: **16.11.2001 JP 2001351938**

(71) Applicant: **NISSHINBO INDUSTRIES, INC.**
Chuo-ku, Tokyo (JP)

(72) Inventors:
• **Suzuki, Osamu, c/o Nisshinbo Ind., Inc.**
Chiba-shi, Chiba (JP)
• **Ichihara, Tatsuo, /o Nisshinbo Ind., Inc.**
Chiba-shi, Chiba (JP)

(74) Representative: **Tombling, Adrian George et al**
Withers & Rogers
Goldings House
2 Hays Lane
London SE1 2HW (GB)

(54) **Oligonucleotide array for detecting the methylation state**

(57) Presence or absence of methylation of C located on 5' side of G in a sample DNA comprising a target sequence containing a dinucleotide consisting of C that may be methylated and a nucleotide on the 3' side of the C (CpN dinucleotide) is determined based on a result of hybridization performed for a plurality of capture oligonucleotides immobilized on a base material and including at least an oligonucleotide having a nucleotide sequence complementary to or identical to a nucleotide sequence corresponding to the target sequence in

which C other than C in the CpN dinucleotide is replaced with T and an oligonucleotide having a nucleotide sequence complementary to or identical to a nucleotide sequence corresponding to the target sequence in which all of C's are replaced with T's and the sample DNA in which cytosines not methylated are converted into uracils by deamination or an amplification product thereof.

DescriptionField of the Invention

5 [0001] The present invention relates to an oligonucleotide-immobilized substrate and method for detecting methylation of cytosine in DNA. More precisely, the present invention provides a substrate or base material for elucidating a cause of disease invited by abnormality of genes by detecting methylated cytosines, which are present and found in a large amount in regulatory sequences for gene expression and so forth, and thereby determining prognostic treatment of the disease.

10

Description of the Related Art

[0002] Methylation of DNA plays an important role in regulation of replication and expression of DNA and so forth. In eucaryocytes, methylation of DNA is frequently occurs at the 5'-position of C (cytosine) present on the 5' side of G (guanine) (henceforth referred to as "CpG dinucleotide"). In particular, many CpG dinucleotides are found in promoter regions of many genes, and such a region is called CpG island (Bird, A., Cell, 70, 5-8, 1992). Although most of these CpG islands of autosome are generally methylated, CpG islands crowdedly exist in promoter regions are not methylated (Ng, H-H. et al., Curr. Opin. Genet. Dev., 9, 158-163, 1999). It is also known that CpG islands in the promoter regions of P16 and P15, which are tumor suppressor genes, are methylated in leukemia or myeloma, and cancerization is caused by inactivation or change of expression amounts of these genes as a result of the methylation (Shu-Xia Gao et al., Leukemia Res., 24, 39-46, 2000; M. Gonzalez et al., Leukemia, 14, 183-187, 2000).

20 [0003] Further, it is also reported that C located on the 5' side of a nucleotide other than G may also be methylated (Gruenbaum, H., et al, Nature, 292:860-62, 1981).

[0004] Furthermore, methylation is a modification scheme of DNA responsible for epigenetic change, and in genome imprinting, there is a mechanism for methylating either one of allelic genes for suppression of expression to suppress the expression so that a gene derived from one of parents should be expressed. Therefore, if the state of methylation is changed, there may be caused onsets of viviparous fatality, hereditary diseases and so forth (Li, E., et al., Cell, 69, 915-926, 1992; Okano, M., et al., Cell, 99, 247-257, 1999; Xu, G-L., Nature, 402, 187-191, 1999).

[0005] Based on the above, it can be said that methylation of cytosine plays a significant role in control of gene expression, and change of the methylation pattern should cause diseases and so forth. Therefore, elucidation of the methylation pattern is important information for treatment and inference of prognosis of diseases.

30 [0006] Cytosine that is not methylated is easily converted into uracil by deamination with sodium bisulfite (Shapiro, R., et al., J. Amer. Chem., 92, 422, 1970). On the other hand, methylated cytosine is not converted into uracil even by a treatment with sodium bisulfite. Therefore, by treating DNA derived from a specimen with sodium bisulfite, DNA in which only methylated cytosines are converted into uracils can be obtained.

35 [0007] In order to detect methylated cytosine using a specimen DNA treated with sodium bisulfite, the following methods (1) and (2) are used.

(1) Sequence analysis

40

[0008] There is a method of treating a genome derived from a specimen with sodium bisulfite, amplifying it by polymerase chain reaction (PCR) and performing sequence analysis (Marianné, F., et al., Proc. Natl. Acad. Sci. USA, 89, 1827-1831, 1992). It is also possible to clone an amplified region to perform mapping of methylation.

45 [0009] In this method, sequence analysis is an essential technique for mapping of methylated cytosines. However, since a regulatory region containing CpG islands has a length of 1-2 kilobases, sequencing reactions must be performed for multiple times. Therefore, it is hardly considered an easy method. Furthermore, since an expensive automatic sequencer and a dangerous radioisotope are used, it cannot be said a simple and convenient method. Moreover, it is difficult to deal many specimens in the sequence analysis.

[0010] Furthermore, it is necessary to obtain information on whether cytosines to be annealed to 3' end of primer used in the sequence analysis are modified with methyl groups beforehand. Therefore, several procedures must be required in order to elucidate whether cytosines of CpG's are methylated.

50

(2) Methylation-specific PCR

55 [0011] A PCR primer having A (adenine) or G (guanine) at the 3' end is prepared and used to perform PCR using DNA treated with sodium bisulfite as a template (James G.H., et al., Proc. Natl. Acad. Sci. USA, 93, 9821-9826, 1996). The obtained amplification product is analyzed by electrophoresis. In this procedure, when amplification can be confirmed by using a primer having T at the 3' end, it is confirmed that cytosine at a position corresponding to the afore-

mentioned T of the specimen DNA should be methylated. On the other hand, when amplification can be confirmed by using a primer having G at the 3' end, it is confirmed that the cytosine should not be methylated. Use of this procedure for each CpG island enables mapping of methylated cytosines.

[0012] In this procedure, however, it is necessary to prepare specific PCR primers for each CpG island. That is, at least three kinds of primers including two kinds of primers having G or A at 3' end of primers and a primer for the reverse direction are required for each CpG. Therefore, for mapping of methylated cytosines in a CpG rich regulation region, it is necessary to prepare an enormous number of PCR primers, perform PCR for an enormous number of times and analyze an enormous number of amplified PCR products by electrophoresis. Furthermore, if multiple specimens are investigated by this technique, PCR must be performed for an inestimable number of times, and therefore it is difficult to perform such investigation by this technique.

Summary of the Invention

[0013] An object of the present invention is to provide a method for detecting methylation of C in DNA, which enables quick detection of methylated cytosines in a large number of sites in a large number of DNA samples or DNA's in a simple and convenient manner, for example, in mapping of methylated cytosines in a CpG rich regulation region and so forth.

[0014] The inventors of the present invention assiduously studied in order to achieve the aforementioned object. As a result, they found that presence or absence of methylation of C in CpG dinucleotides can be quickly detected in a simple and convenient manner by preparing a substrate on which an oligonucleotide having a nucleotide sequence complementary to or identical to a nucleotide sequence corresponding to a target sequence in a sample DNA in which C's other than C's in CpG dinucleotides are replaced with T's, and an oligonucleotide having a nucleotide sequence complementary to or identical to a nucleotide sequence corresponding to the target sequence in which all of C's are replaced with T's are immobilized and allowing hybridization of the oligonucleotides on the substrate and the sample DNA in which non-methylated cytosines are converted into uracils by deamination. Thus, they accomplished the present invention.

[0015] That is, the present invention provides the followings.

(1) An oligonucleotide-immobilized substrate used for detecting presence or absence of methylation of C in a sample DNA, on which multiple kinds of capture oligonucleotides are immobilized, wherein

the sample DNA contains a target sequence containing a dinucleotide consisting of C that can be methylated and a nucleotide on the 3' side of the C (henceforth referred to as "CpN dinucleotide"),

the capture oligonucleotides include at least an oligonucleotide having a nucleotide sequence complementary to or identical to a nucleotide sequence corresponding to the target sequence in which C's other than C in the CpN dinucleotide are replaced with T's and an oligonucleotide having a nucleotide sequence complementary to or identical to a nucleotide sequence corresponding to the target sequence in which all of C's are replaced with T's, and

the presence or absence of methylation is detected based on hybridization of the sample DNA in which non-methylated C's have been converted into U's by deamination or an amplification product thereof and the capture oligonucleotides.

(2) The oligonucleotide-immobilized substrate according to (1), wherein the nucleotide on the 3' side of the C is A, G or T.

(3) The oligonucleotide-immobilized substrate according to (2), wherein the nucleotide on the 3' side of the C is G.

(4) The oligonucleotide-immobilized substrate according to any one of (1) to (3), wherein the capture oligonucleotides are immobilized via carbodiimide groups.

(5) The oligonucleotide-immobilized substrate according to any one of (1) to (4), wherein the capture oligonucleotides are immobilized as dots on a base material, and each dot has an occupied area of 0.1 cm² or less.

(6) The oligonucleotide-immobilized substrate according to any one of (1) to (5), wherein the capture oligonucleotides are oligonucleotides of 30-mer or less.

(7) The oligonucleotide-immobilized substrate according to any one of (1) to (6), wherein the sample DNA contains multiple target sequences, and capture oligonucleotides corresponding to each of the target sequences were immobilized.

(8) A method for detecting presence or absence of methylation of C in a sample DNA containing a target sequence containing a CpN dinucleotide, wherein

multiple kinds of capture oligonucleotides immobilized on a base material and including at least an oligonucleotide having a nucleotide sequence complementary to or identical to a nucleotide sequence corresponding to the target sequence in which C's other than C in the CpN dinucleotide are replaced with T's and an oligonucleotide having a nucleotide sequence complementary to or identical to a nucleotide sequence corresponding to the target sequence in which all of C's are replaced with T's are hybridized with the sample DNA in which non-methylated

C's have been converted into U's by deamination or an amplification product thereof, and the presence or absence of methylation is detected based on the result of the hybridization.

(9) The method according to claim 8, wherein the non-methylated C's have been deaminated by treatment with sodium bisulfite.

[0016] According to the present invention, methylated cytosine and cytosine not methylated in DNA can be quickly distinguished in a simple and convenient manner.

Preferred Embodiments of the Invention

[0017] Hereafter, the present invention will be explained in detail.

[0018] The oligonucleotide-immobilized substrate of the present invention is used in order to detect presence or absence of methylation of C in a sample DNA. The sample DNA comprises a target sequence containing a dinucleotide consisting of C that can be methylated and a nucleotide on the 3' side of the C (CpN dinucleotide). The C that can be methylated usually refers to C present on the 5' side of G, however, it also refers to C present on the 5' side of a nucleotide of A, G or T, when the C can be methylated.

[0019] One target sequence or multiple target sequences may be present in the sample DNA. Further, one or more CpN dinucleotides may exist in one target sequence.

[0020] As the nucleotide on the 3' side of C, A, G and T can be mentioned, and it is preferably G.

[0021] The oligonucleotide-immobilized substrate comprises a base material and multiple kinds of capture oligonucleotides immobilized on the base material. The capture oligonucleotides include at least an oligonucleotide having a nucleotide sequence complimentary to or identical to a nucleotide sequence corresponding to the target sequence in which C's other than C's in CpN dinucleotides are replaced with T's (henceforth also referred to as "C-specific oligonucleotide") and an oligonucleotide having a nucleotide sequence complimentary to or identical to a nucleotide sequence corresponding to the target sequence in which all of C's are replaced with T's (henceforth also referred to as "T-specific oligonucleotide").

[0022] If such capture oligonucleotides as described above are allowed to hybridize with the sample DNA in which non-methylated cytosines are converted into uracils by deamination or an amplification product thereof, the C-specific oligonucleotide hybridizes to the target sequence, but the T-specific oligonucleotide does not hybridize thereto. That is, if C's in CpN dinucleotides are methylated, these C's are not converted into uracils, but C's other than C's in CpN dinucleotides are converted into uracils. On the other hand, if C's of CpN dinucleotides in the target sequence are not methylated, all of C's including those C's of CpN dinucleotides are converted into uracils. Therefore, the C-specific oligonucleotide does not hybridize to the target sequence, but the T-specific oligonucleotide hybridizes thereto. Thus, presence or absence of methylation of C's in CpN dinucleotides can be detected based on the result of the aforementioned hybridization.

[0023] Examples of a capture oligonucleotide in which CpN dinucleotide is CpG and a target sequence are shown in Fig. 1. SEQ ID NO: 5 shows a model of nucleotide sequence of sample DNA in which C's are not deaminated. SEQ ID NO: 6 shows a model of nucleotide sequence in which all of C's of the sample DNA are deaminated and thus converted into uracils. This model represents DNA in which methylation of C does not occur. SEQ ID NO: 7 shows a model of nucleotide sequence in which C's of two CpG dinucleotides contained in the aforementioned sample DNA are conserved as they are and all of the other C's are converted into uracils. This model represents DNA in which C's of CpG dinucleotides are methylated.

[0024] SEQ ID NOS: 1 and 2 show capture oligonucleotides corresponding to the target sequence containing CpG dinucleotide on the 5' end side among two of the CpG dinucleotides. SEQ ID NO: 1 shows a C-specific oligonucleotide, and SEQ ID NO: 2 shows a T-specific oligonucleotide. SEQ ID NOS: 3 and 4 show capture oligonucleotides corresponding to the target sequence containing CpG dinucleotide on the 3' end side among two of the CpG dinucleotides. SEQ ID NO: 3 shows a C-specific oligonucleotide, and SEQ ID NO: 4 shows a T-specific oligonucleotide. The capture oligonucleotides of SEQ ID NOS: 1 and 3 and the capture oligonucleotides of SEQ ID NOS: 2 and 4 hybridize to complementary strands of DNA of SEQ ID NOS: 7 and 6, respectively.

[0025] The sample DNA may be a single-stranded DNA or a double-stranded DNA. When the sample DNA is a single-stranded DNA, the capture oligonucleotides comprises an oligonucleotide having a nucleotide sequence complementary to a nucleotide sequence of target sequence in which C's other than C's of CpN dinucleotides are replaced with T's and an oligonucleotide having a nucleotide sequence complementary to a nucleotide sequence of target sequence in which all of C's are replaced with T's. When the sample DNA is a double-stranded DNA, the capture oligonucleotides comprises a strand containing a target sequence and a strand complementary thereto, and since CpN dinucleotides are symmetrically present in each strand, the capture oligonucleotides may be the same oligonucleotides as those in the case of single-stranded DNA or oligonucleotides having nucleotide sequences complementary thereto.

[0026] Although sequence and length of the capture oligonucleotides are not particularly limited so long as difference

of one nucleotide can be detected by hybridization, the capture oligonucleotides usually have a length of preferably 10- to 30-mer, more preferably 10- to 25-mer, particularly preferably 13- to 25-mer.

[0027] Oligonucleotides used as the capture oligonucleotides can be chemically synthesized by a usual solid-phase synthesis method. The aforementioned capture oligonucleotides are immobilized on a substrate. At least one pair of capture oligonucleotides corresponding to one target sequence (T-specific oligonucleotide and C-specific oligonucleotide) are immobilized, and two or more of capture oligonucleotide pairs corresponding to two or more target sequences may be immobilized on a substrate.

[0028] Each oligonucleotide is preferably immobilized at a 5' end portion or 3' end portion on a base material. The base material used for the present invention is not particularly limited so long as it can immobilize oligonucleotides by physical adsorption or chemical bonding and bear usual hybridization conditions. Specifically, there can be mentioned those insoluble in solvents used for immobilization and hybridization of oligonucleotides etc. and being in the form of solid or gel at an ordinary temperature or within a temperature range around it (e.g., 0°C to 100°C). The expression that "a base material is insoluble in a solvent" means that, after a substance having a property of bonding to oligonucleotides such as carbodiimide group is carried on the base material and oligonucleotides are immobilized on the base material as described later, the base material is substantially insoluble in various solvents including aqueous solvents and organic solvents used in various process steps when it is used as, for example, DNA chip.

[0029] Specific examples of the material of such a base material include plastics, inorganic polymers, metals, natural polymers, ceramics and so forth.

[0030] Specific examples of the plastics include polyethylene, polystyrene, polycarbonate, polypropylene, polyamide, phenol resin, epoxy resin, polycarbodiimide resin, polyvinyl chloride, polyvinylidene fluoride, polyethylene fluoride, polyimide, acrylic resin and so forth.

[0031] Specific examples of the inorganic polymers include glass, quartz crystal, carbon, silica gel, graphite and so forth.

[0032] Specific examples of the metals include gold, platinum, silver, copper, iron, aluminum, magnet, paramagnet, apatite and so forth.

[0033] Examples of the natural polymers include polyamino acids, cellulose, chitin, chitosan, alginic acid and derivatives thereof.

[0034] Specific examples of the ceramics include alumina, silica, silicon carbide, silicon nitride, boron carbide and so forth.

[0035] Examples of shape of the aforementioned base materials include, for example, film, plate, particle, molded parts (bead, strip, well of multi-well plate, strip, tube, mesh, continuous foam, membrane, paper, needle, fiber, plate, slide, cell culture vessel etc.), latex and so forth. Sizes of these are not particularly limited.

[0036] When oligonucleotides are immobilized on the base material, the oligonucleotides may be immobilized directly on the base material, or a carrier may be carried on the base material and the oligonucleotides may be immobilized on the base material via the carrier. The base material itself may have a property of bonding to the oligonucleotides, or it may be one that can immobilize the oligonucleotides via a ligand having a property of bonding to oligonucleotides. The term "carry" used herein means that the oligonucleotides do not substantially dissociate from the base material in various solvents including aqueous solvents and organic solvents used when the oligonucleotides are immobilized on the base material, the oligonucleotide-immobilized base material is used as a DNA chip and so forth.

[0037] The carrier used for the present invention may be carried by utilizing only physical adhesion or it may be chemically carried via a covalent bond or the like so long as it is carried on the aforementioned base material. Further, the carrier may be carried on the entire surface of the base material or a part thereof, as required.

[0038] Examples of the carrier include low molecular weight organic molecules, plastics, inorganic polymers, metals, natural polymers, ceramics and so forth.

[0039] Specific examples of the low molecular weight organic molecules include carbodiimide group-containing compounds, isocyanate group-containing compounds, nitrogen yperite group-containing compounds, aldehyde group-containing compounds, amino group-containing compounds and so forth.

[0040] Specific examples of the plastics include polyethylene, polystyrene, polycarbonate, polypropylene, polyamide, phenol resin, epoxy resin, polycarbodiimide resin, polyvinyl chloride, polyvinylidene fluoride, polyethylene fluoride, polyimide, acrylic resin and so forth.

[0041] Specific examples of the inorganic polymers include glass, quartz crystal, carbon, silica gel, graphite and so forth.

[0042] Specific examples of the metals include gold, platinum, silver, copper, iron, aluminum, magnet, paramagnet, apatite and so forth.

[0043] Examples of the natural polymers include polyamino acids, cellulose, chitin, chitosan, alginic acid and derivatives thereof.

[0044] Specific examples of the ceramics include alumina, silica, silicon carbide, silicon nitride, boron carbide and so forth.

[0045] Such a carrier has a highly adhesive property to the aforementioned base material, and it is adhered to the base material by utilizing this adhesive property. A typical shape of the carrier in the case where it is carried on the base material by utilizing physical adhesion property is a coated film. As the method of providing the carrier as a coated film carried on the base material, there can be used known methods such as coating using spraying, dipping, brushing, stamp, vaporization, film coater and so forth.

[0046] For example, in order to provide a resin having carbodiimide groups carried on the whole surface of glass base material, a glass base material is first immersed in a solution obtained by dissolving an amino-substituted organoalkoxysilane such as 3-aminopropyltriethoxysilane in a suitable solvent under a temperature condition of 70 to 80°C for about 2 to 3 hours, then the base material is taken out, and after the solution is washed out, the base material is dried by heating under a temperature condition of 100 to 120°C for about 4 to 5 hours. After the drying, the base material can be immersed into an appropriate solvent, and the solvent can be added with a carbodiimide resin and stirred for washing under a temperature condition of 30 to 170°C for about 12 hours. Further, it is also possible to allow the amino group of the 3-aminopropyltriethoxysilane and a functional group of nitrogen yperite group other than the oligonucleotide binding group to react by using an appropriate solvent to introduce the nitrogen yperite group on the surface of glass base material.

[0047] Introduction of various functional groups onto surfaces of such materials as described above has conventionally and generally been used, and methods therefor are known. Therefore, as also for cases where functional groups other than amino group are allowed to exist on a glass base material or the base material consists of a material other than glass, functional groups can be introduced onto the base material surface by using such known techniques.

[0048] Furthermore, some plastic base materials among those mentioned above properly have such functional groups as mentioned above. In such a case, the materials can be used as they are for the production of the base material without introducing functional groups onto surfaces thereof. Further, even such plastic base materials may be further introduced with functional groups and used for the production of the base material.

[0049] The capture oligonucleotides are immobilized on such a base material as described above at a 5' end portion or 3' end portion. The method for immobilizing oligonucleotides can suitably be determined according to types of base material, functional groups on the surface of the base material, ligand and so forth.

[0050] The capture oligonucleotides may be bonded with a homopolymer consisting of three or more nucleotides on the side of an end to be immobilized on the base material. When a base material having carbodiimide groups on the surface is used, in particular, the oligonucleotides having such a homopolymer are firmly immobilized on the base material.

[0051] A known method can be used as the method of bonding such a homopolymer to ends of the oligonucleotides. For example, there can be specifically mentioned a method of synthesizing an oligonucleotide so that three or more nucleotides should be polymerized as an integral part of the oligonucleotide by using a commercially available nucleic acid synthesizer. There can also be mentioned a method of binding a homopolymer to an oligonucleotide by using a chemical or enzymatic technique and so forth. The nucleobases constituting the homopolymer are selected from adenine, guanine, cytosine or thymine when the nucleic acid is DNA, or selected from adenine, guanine, cytosine or uracil when it is RNA.

[0052] The homopolymer preferably has a length of 3 to 100 nucleotides, more preferably 5 to 50 nucleotides, particularly preferably 10 to 40 nucleotides. If the number of nucleotide is 2 or less, a sufficient amount of nucleic acid cannot be immobilized on the base material. If the number of nucleotides is 101 or more, yield is markedly reduced in the nucleic acid production process.

[0053] The homopolymer may be formed from a homopolymer consisting of a certain kind of nucleotides and another homopolymer consisting of another kind of nucleotides ligated together.

[0054] Further, the 5' end of the nucleotide may be immobilized via an amino linker.

[0055] The oligonucleotides are preferably immobilized in dot-like areas. To immobilize in dot-like areas means that the areas on which the oligonucleotides are immobilized have a size sufficiently smaller than the size of the base material in such a degree that a plurality of the oligonucleotide-immobilized sites can be provided on the base material. Although shape of the dots is not particularly limited, it is generally preferably a circular shape. The oligonucleotides are usually immobilized on a plurality of sites on the base material, and the oligonucleotide-immobilized substrate is prepared as a so-called DNA array or DNA chip.

[0056] Specifically, the oligonucleotides are usually provided, for example, so as to be contained in water or a buffer so that activities of the oligonucleotides to be immobilized should be maintained during contact of the oligonucleotide and the base material for reaction. Temperature for the contact is preferably about 0 to 100°C so that the activities of the oligonucleotides should not be degraded.

[0057] The immobilization can also be attained by irradiation of electromagnetic waves such as UV rays after the contact of the oligonucleotides and the base material. Further, the immobilization can also be attained by contacting a mixture of the oligonucleotides and a known compound such as carbodiimide resin, nitrogen yperite, polyamino acids and nitrocellulose, which are chemically bonded or physically associated, with the base material. Even in such a case,

the immobilization can also be attained by irradiation of electromagnetic waves such as UV rays.

[0058] In the present invention, means for providing oligonucleotides, usually in the form of water or buffer containing the oligonucleotides, in dot-like areas on the base material includes a method of utilizing a dispenser, method of utilizing a pin, method of utilizing bubble jet and so forth. However, the present invention is not limited to these. Such apparatuses

5 for providing solutions in small amounts are commercially available, and they can be used for the present invention. [0059] The capture oligonucleotide-immobilized base material is preferably brought into contact with an excessive amount of bovine serum albumin (BSA), casein, salmon sperm DNA or the like to block unreacted portions after the capture oligonucleotides are immobilized on the base material in dot-like areas as described above in order to prevent non-specific binding of sample DNA.

10 [0060] In the present invention, the sample or amplification product thereof is hybridized with the capture oligonucleotides by using the aforementioned capture oligonucleotide-immobilized substrate.

[0061] The sample DNA is not particularly limited so long as it contains CpN dinucleotides and presence of methylation of C is expected for it, and DNA of various organisms may be used depending on the purpose. The sample DNA is prepared from microbial cell, various tissues of animals or plants. The sample DNA can be prepared in the same 15 manner as usual preparation of DNA from cells. Further, although DNA prepared from cells can also be used as it is as the sample DNA, DNA of which target sequence or a region including the target sequence is amplified by PCR method or the like may also be used.

[0062] In the conventional methylation-specific PCR, at least three kinds of primers are required for one CpN. However, according to the present invention, a region containing multiple CpN's can be amplified with two kinds of primers. 20 Further, in the methylation-specific PCR, a primer is designed so that its 3' end should correspond to cytosine of CpN. Therefore, when many CpN sequences exist as in CpG island, methylation of CpN can be detected only for a relatively narrow region. On the other hand, according to the present invention, a primer may be designed so that C of CpN should not correspond to the 3' end, and thus PCR amplification is possible irrespective of methylation of C in CpN.

[0063] As for the sample DNA or its amplification product, C's not methylated are converted into uracils by deamination prior to the hybridization. This deamination of non-methylated C's can be performed by treating the sample DNA 25 with bisulfite such as sodium bisulfite. Specifically, a solution containing the sample DNA is added with sodium bisulfite (pH 5) at a concentration of 2.5 M to 3.0 M and heated at 50°C for 16 hours (J.G. Herman et al., Proc. Natl. Acad. Sci. USA, 93, 9821-9826, 1996). After the reaction with heating, the sample DNA is adsorbed on a silica-based filter for purification to remove the sodium bisulfite. After the removal, the sample DNA is collected from the silica-based filter 30 and concentrated by ethanol precipitation or the like.

[0064] Although specific procedure of the hybridization is not particularly limited, it can be performed by, for example, immersing a substrate on which the capture oligonucleotides are immobilized in a solution containing the sample DNA, or spotting a solution containing the sample DNA onto areas where the capture oligonucleotides are immobilized. Further, areas where the capture oligonucleotides are immobilized may be covered with frames so that the frames 35 should include the areas, and a solution containing the sample DNA may be poured into the frames.

[0065] The solution is not particularly limited so long as it allows hybridization of DNA, and various buffers can be used for it. For example, Tris-HCl having pH of about 6.5 to 8 can be mentioned. Usually, the solution is heated to a temperature at which base pairs formed in molecules of DNA or oligonucleotides dissociate, e.g., 90 to 100°C, and then adjusted to a temperature at which the capture oligonucleotides and a target sequence in the sample nucleic acid 40 anneal. Specifically, this temperature is preferably 5 to 80°C in general, although it depends on length of the capture oligonucleotides.

[0066] Although the method for detecting the hybridization is not particularly limited, it can be detected by, for example, labeling the sample nucleic acid with a labeling substance beforehand and detecting the label after the hybridization and washing of the substrate. Although the labeling substance is not particularly limited, examples thereof include 45 substances usually used for detection of hybridization, for example, radiolabels, fluorescent dyes, biotin, haptens, antigens and so forth. When biotin is used as a labeling substance, for example, a conjugate of a protein specifically binding to biotin (avidin or streptavidin) and an enzyme chemically bonded to biotin can be bound after the hybridization operation, and a reaction can be performed by adding a compound that is degraded with the enzyme to form a dye that can deposit to readily detect presence or absence and location of hybridization.

50 Examples

[0067] Hereafter, the present invention will be explained more specifically with reference to the following example. In the following example, investigation was performed for explaining the present invention by using a sequence of 55 human NF-IL6 gene (GenBank Accession: AF350408) as a model system. However, application of the present invention is not limited only to this gene.

<1> Synthesis of oligonucleotides

[0068] Oligonucleotides having an amino group or hydroxyl group at the 5' end were synthesized by using an oligonucleotide synthesizer (Perkin-Elmer Applied Biosystems), deprotected and dried in a conventional manner. These dried oligonucleotides were dissolved in 10 mM Tris-HCl (pH 7.5), 1 mM EDTA buffer to prepare 100 pmol/μL oligonucleotide solutions. Sequences of the synthesized oligonucleotides are shown as SEQ ID NOS: 1-4 in Sequence Listing.

10 SEQ ID NO: 1 5'-cctaaaccc gattatttat-3'

15 SEQ ID NO: 2 5'-cctaaaccc aattatttat-3'

20 SEQ ID NO: 3 5'-ctctaactcg ctaaaattt-3'

25 SEQ ID NO: 4 5'-ctctaactca ctaaaattt-3'

<2> Spotting of oligonucleotide on substrate (case of using oligonucleotide having an amino group at 5' end)

25 [0069] A solution of oligonucleotide having an amino group at 5' end in a volume of 10 μL was mixed with 10 μL of a microspotting solution (TeleChem International Inc.) and dispensed on a microtiter plate (Greiner Laboratory Ltd.). Silanized slide glass (Matsunami Glass Ind., Ltd.) was mounted on a predetermined position on a spotting machine, and the spotting machine was operated. After completion of the spotting, the slide glass was exposed to steam from hot water for several seconds. Then, the slide glass was irradiated with an ultraviolet ray of 30 mJ. After further exposure to steam for several seconds, the slide glass was placed on a hot plate to remove moisture. The slide glass was rinsed with 0.1% sodium dodecylsulfate aqueous solution and then rinsed with distilled water. The slide glass was immersed in 100 mM Tris-HCl (pH 7.5), 100 mM NaCl, 0.1% Triton X-100 containing 3% BSA (bovine serum albumin) at room temperature for 30 minutes for blocking. Then, the slide glass was dried at room temperature and washed with 10 mM Tris-HCl (pH 7.5), 1 mM EDTA buffer. The slide glass was dried again at room temperature and stored in a cold dark place in a dried state until use.

<3> Spotting of oligonucleotide on substrate (case of using oligonucleotide having OH group at 5' end)

40 [0070] A solution of oligonucleotide having a hydroxyl group at 5' end in a volume of 10 μL was mixed with 10 μL of a spotting solution (2 M sodium chloride aqueous solution) and dispensed on a microtiter plate (Greiner Laboratory Ltd.). Slide glass having carbodiimide groups was disposed on a predetermined position on a spotting machine, and the spotting machine was operated. After completion of the spotting, the slide glass was immersed in 100 mM Tris-HCl (pH 7.5), 100 mM NaCl, 0.1% Triton X-100 containing 3% BSA (bovine serum albumin) at room temperature for 30 minutes for blocking. Then, the slide glass was dried at room temperature and washed with 10 mM Tris-HCl (pH 7.5), 1 mM EDTA buffer. The slide glass was dried again at room temperature and stored in a cold dark place in a dried state until use.

<4> Preparation of nucleic acid probe

50 [0071] An oligonucleotide having a hydroxyl group at the 5' end was synthesized by using an oligonucleotide synthesizer (Perkin-Elmer Applied Biosystems), deprotected and dried in a conventional manner. The dried oligonucleotide was dissolved in 10 mM Tris-HCl (pH 7.5), 1 mM EDTA buffer to prepare a 100 pmol/μL oligonucleotide solution. Sequence of the synthesized oligonucleotide is shown as SEQ ID NO: 5 in Sequence Listing.

55 [0072] The oligonucleotide shown as SEQ ID NO: 5 in an amount of 10 μg was methylated by using CpGenome DNA Modification Kit (Intergen) to prepare an oligonucleotide in which all of C's in the sequence were converted into U's (SEQ ID NO: 6). Further, an oligonucleotide having the sequence shown as SEQ ID NO: 6 was synthesized by using a DNA synthesizer. Moreover, an oligonucleotide in which only C's of CpG's were methylated and not converted into U's and other C's were all converted into U's (SEQ ID NO: 7) was also synthesized by using a DNA synthesizer.

Furthermore, after the synthesis, biotin was introduced into the 5' end of the oligonucleotides in a conventional manner.

SEQ ID NO: 5

5'-ccctt ataaataacc gggctcagga gaaactttag cgagtcagag-3'

SEQ ID NO: 6

5'-UUUtt ataaataaUU gggUtUagga gaaaUtttag UgagtUagag-3'

SEQ ID NO: 7

5'-UUUtt ataaataaUc gggUtUagga gaaaUtttag cgagtUagag-3'

<5> Hybridization

[0073] Each of the nucleic acid probes of SEQ ID NOS: 5-7 prepared in the above aforementioned <4> was taken in a volume of 5 μ L (1 pmol), placed in a 1.5 mL-volume tube, added with 20 μ L of UniHyb Hybridization solution (Telechem International Inc.) and mixed to prepare a hybridization solution. This solution was treated by heating at 70°C for 5 minutes and placed on ice for 5 minutes. This nucleic acid probe in a volume of 10 μ L was placed on each of the substrates on which the oligonucleotides were spotted prepared in the above <2> and <3>, and cover glass was placed on them.

[0074] The substrate was put into Hybridization Cassette (Telechem International Inc.), immersed into water at 42°C in a tank and left for 1 hour under light shielding. The substrate was taken out from Hybridization Cassette and immersed in 2 x SSC (0.75 M NaCl, 0.075 M sodium citrate) at room temperature to remove the cover glass. An operation of immersing the substrate in 0.3 x SSC at 45°C for 5 minutes was performed twice. The substrate was finally transferred into a solution of 2 x SSC.

<6> Chemical coloration reaction

[0075] The substrate was taken out from a vessel, moisture on the area in which the oligonucleotides were not immobilized was wiped off with paper towel, and 200 μ L of Block Ace solution (Dainippon Pharmaceutical Co., Ltd.) was placed on the oligonucleotide-immobilized area. After the substrate was left at room temperature for 30 minutes, the solution was sucked up with a dispenser, and 200 μ L of a solution obtained by adding one drop each of avidin DH and biotinylated peroxidase (Vector Laboratories, Inc.) to 5 mL of TBST solution (50 mM Tris-HCl (pH 7.5), 0.15 M NaCl, 0.05% Tween 20) and mixing them was placed on the oligonucleotide-immobilized area of the substrate and left at room temperature for 30 minutes. The solution was sucked up with a dispenser, and the substrate was transferred to a vessel containing TBST solution and washed at room temperature for 5 minutes with shaking. The solution was once discarded, and fresh TBST solution was added to the vessel to wash the substrate at room temperature for 5 minutes with shaking. The substrate was taken out from the vessel, and moisture on the area in which the oligonucleotides were not immobilized was wiped off with paper towel. On the oligonucleotide-immobilized area, 200 μ L of TMB (Vector Laboratories, Inc.) was placed, and a reaction was allowed at room temperature for 20 minutes. Then, the substrate was washed with deionized water to terminate the enzymatic reaction.

<7> Detection of chemical coloration

[0076] The coloring image on the substrate were captured and stored as a TIFF image in a computer by using an OA scanner (NEC Multireader 600SR) and Photoshop Ver. 5.0 (Adobe Systems). The result is shown in Fig. 2. In this image, pigmentation formed by chemical coloration, if present, indicated that the oligonucleotide immobilized on the substrate (capture oligonucleotide) and the nucleic acid probe were fully complementary to each other and thus a duplex was formed.

Sequence Listing

5

<110> Nisshinbo Industries, Inc.

10

<120> Oligonucleotide-Immobilized Substrate for
Detecting Methylation

15

<130> OP1390

<140>

<141> 2002-11-

20

<150> JP 2001-351938

<151> 2001-11-16

25

<160> 7

<170> PatentIn version 3.0

30

<210> 1

<211> 19

<212> DNA

35

<213> Artificial/Unknown

<220>

<221> misc_feature

40

<222> ().().

<223> Description of Artificial Sequence: capture
oligonucleotide

45

<400> 1

cctaaaccc gattatttat

19

50

<210> 2

<211> 19

<212> DNA

55

<213> Artificial/Unknown

EP 1 312 685 A2

5 <220>
 <221> misc_feature
 <222> ()..()
 <223> Description of Artificial Sequence: capture
 oligonucleotide

 10 <400> 2
 ccctaaaccca attatttat 19

 15 <210> 3
 <211> 19
 <212> DNA
 <213> Artificial/Unknown

 20 <220>
 <221> misc_feature
 <222> ()..()
 25 <223> Description of Artificial Sequence: capture
 oligonucleotide

 30 <400> 3
 ctctaaactcg ctaaaattt 19

 35 <210> 4
 <211> 19
 <212> DNA
 <213> Artificial/Unknown

 40 <220>
 <221> misc_feature
 <222> ()..()
 45 <223> Description of Artificial Sequence: capture
 oligonucleotide

 50 <400> 4
 ctctaaactca ctaaaattt 19

 55 <210> 5
 <211> 45
 <212> DNA
 <213> Artificial/Unknown

<220>
 <221> misc_feature
 5 <222> ()..()
 <223> Description of Artificial Sequence: probe
 oligonucleotide -
 10
 <400> 5
 cccttataaa taaccgggct caggagaaac tttagcgagl cagag 45
 15
 <210> 6
 <211> 45
 <212> DNA
 <213> Artificial/Unknown
 20
 <220>
 <221> misc_feature
 25 <222> ()..()
 <223> Description of Artificial Sequence: probe
 oligonucleotide_
 30
 <400> 6
 uuuttataaa taauuggggt uaggagaaau tttagugagl uagag 45
 35
 <210> 7
 <211> 45
 <212> DNA
 <213> Artificial/Unknown
 40
 <220> -
 <221> misc_feature -
 45 <222> ()..()
 <223> Description of Artificial Sequence: probe
 oligonucleotide -
 50
 <400> 7
 uuuttataaa taauuggggt uaggagaaau tttagcgagl uagag 45

55

Claims

1. An oligonucleotide-immobilized substrate used for detecting presence or absence of methylation of C in a sample

DNA, on which multiple kinds of capture oligonucleotides are immobilized, wherein
the sample DNA contains a target sequence containing a dinucleotide consisting of C that can be methylated
and a nucleotide on the 3' side of the C (henceforth referred to as "CpN dinucleotide"),

the capture oligonucleotides include at least an oligonucleotide having a nucleotide sequence complimentary
to or identical to a nucleotide sequence corresponding to the target sequence in which C's other than C in the CpN
dinucleotide are replaced with T's and an oligonucleotide having a nucleotide sequence complimentary to or identical
to a nucleotide sequence corresponding to the target sequence in which all of C's are replaced with T's, and
the presence or absence of methylation is detected based on hybridization of the sample DNA in which non-
methylated C's have been converted into U's by deamination or an amplification product thereof and the capture
oligonucleotides.

2. The oligonucleotide-immobilized substrate according to claim 1, wherein the nucleotide on the 3' side of the C is A, G or T.
3. The oligonucleotide-immobilized substrate according to claim 2, wherein the nucleotide on the 3' side of the C is G.
4. The oligonucleotide-immobilized substrate according to any one of claims 1-3, wherein the capture oligonucleotides are immobilized via carbodiimide groups.
5. The oligonucleotide-immobilized substrate according to any one of claims 1-4, wherein the capture oligonucleotides are immobilized as dots on a base material, and each dot has an occupied area of 0.1 cm² or less.
6. The oligonucleotide-immobilized substrate according to any one of claims 1-5, wherein the capture oligonucleotides are oligonucleotides of 30-mer or less.
7. The oligonucleotide-immobilized substrate according to any one of claims 1-6, wherein the sample DNA contains multiple target sequences, and capture oligonucleotides corresponding to each of the target sequences were immobilized.
8. A method for detecting presence or absence of methylation of C in a sample DNA containing a target sequence containing a CpN dinucleotide, wherein
multiple kinds of capture oligonucleotides immobilized on a base material and including at least an oligonucleotide having a nucleotide sequence complimentary to or identical to a nucleotide sequence corresponding to the target sequence in which C's other than C in the CpN dinucleotide are replaced with T's and an oligonucleotide having a nucleotide sequence complimentary to or identical to a nucleotide sequence corresponding to the target sequence in which all of C's are replaced with T's are hybridized with the sample DNA in which non-methylated C's have been converted into U's by deamination or an amplification product thereof, and
the presence or absence of methylation is detected based on the result of the hybridization.
9. The method according to Claim 8, wherein the non-methylated C's have been deaminated by treatment with sodium bisulfite.

SEQ ID NO: 1	ataaataatc	gggtttagg	
SEQ ID NO: 2	ataaataatt	gggtttagg	
SEQ ID NO: 3			aaattttag cgagttagag
SEQ ID NO: 4			aaattttag tgagttagag
SEQ ID NO: 5	5'-ccctt ataaataacc	gggctcagga gaaactttag	cgagtcagag-3'
SEQ ID NO: 6	5'-UUUtt ataaataaUU	gggUttUagga gaaaUtttag	UgagtUagag-3'
SEQ ID NO: 7	5'-UUUtt ataaataaUc	gggUttUagga gaaaUtttag	cgagtUagag-3'

Fig. 1



(12) **EUROPEAN PATENT APPLICATION**

(88) Date of publication A3:
12.11.2003 Bulletin 2003/46

(51) Int Cl.7: **C12Q 1/68**

(43) Date of publication A2:
21.05.2003 Bulletin 2003/21

(21) Application number: **02257873.6**

(22) Date of filing: **14.11.2002**

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
IE IT LI LU MC NL PT SE SK TR
Designated Extension States:
AL LT LV MK RO SI

(72) Inventors:
• **Suzuki, Osamu, c/o Nisshinbo Ind., Inc.**
Chiba-shi, Chiba (JP)
• **Ichihara, Tatsuo, /o Nisshinbo Ind., Inc.**
Chiba-shi, Chiba (JP)

(30) Priority: **16.11.2001 JP 2001351938**

(74) Representative: **Tombling, Adrian George et al**
Withers & Rogers
Goldings House
2 Hays Lane
London SE1 2HW (GB)

(71) Applicant: **NISSHINBO INDUSTRIES, INC.**
Chuo-ku, Tokyo (JP)

(54) **Oligonucleotide array for detecting the methylation state**

(57) Presence or absence of methylation of C located on 5' side of G in a sample DNA comprising a target sequence containing a dinucleotide consisting of C that may be methylated and a nucleotide on the 3' side of the C (CpN dinucleotide) is determined based on a result of hybridization performed for a plurality of capture oligonucleotides immobilized on a base material and including at least an oligonucleotide having a nucleotide sequence complementary to or identical to a nucleotide sequence corresponding to the target sequence in

which C other than C in the CpN dinucleotide is replaced with T and an oligonucleotide having a nucleotide sequence complementary to or identical to a nucleotide sequence corresponding to the target sequence in which all of C's are replaced with T's and the sample DNA in which cytosines not methylated are converted into uracils by deamination or an amplification product thereof.



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 02 25 7873

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (In ICL7)
X	US 6 214 556 B1 (OLEK ALEXANDER ET AL) 10 April 2001 (2001-04-10) * abstract * * column 4, line 27 - line 55 * * column 6, line 50 - column 7, line 11 * * column 9, line 53 - column 10, line 6 * * column 17, line 26 - line 50 * ---	1-3,8,9	C12Q1/68
X	DE 198 53 398 C (EPIGENOMICS GMBH) 16 March 2000 (2000-03-16) * abstract * * column 3, line 46 - column 5, line 8 * ---	1,8,9	
Y	EP 1 130 121 A (NISSHIN SPINNING) 5 September 2001 (2001-09-05) * abstract * * page 7, line 10 - page 8, line 4 * * page 2, line 35 - line 41 * * page 7; example 1 * ---	8,9	
X		1-4,6,7	
X	DE 100 13 847 A (EPIGENOMICS AG) 27 September 2001 (2001-09-27) * abstract * * page 2, line 47 - line 55 * * page 3, line 13 - line 21 * * page 3, line 32 - line 44 * * page 4, line 1 - page 8, line 20 * * page 8, line 29 - line 45 * * page 13, line 30 - line 45 * --- -/--	1-3,6-9	TECHNICAL FIELDS SEARCHED (Int. Cl.7) C12Q
The present search report has been drawn up for all claims			
Place of search MUNICH		Date of completion of the search 19 September 2003	Examiner Leber, T
<p>CATEGORY OF CITED DOCUMENTS</p> <p>X: particularly relevant if taken alone Y: particularly relevant if combined with another document of the same category A: technological background O: non-written disclosure P: intermediate document</p> <p>T: theory or principle underlying the invention E: earlier patent document, but published on, or after the filing date D: document cited in the application L: document cited for other reasons =: member of the same patent family, corresponding document</p>			

EPO FORM 1503 (3.12.02) (P4/C01)



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 02 25 7873

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
X	WO 01 76451 A (PIEPENBROCK CHRISTIAN ;BERLIN KURT (DE); EPIGENOMICS AG (DE); OLEK) 18 October 2001 (2001-10-18) * page 3, paragraph 2 * * page 4, paragraph 3 * * page 6, paragraph 2 - page 8, paragraph 2 * * page 10, paragraph 1 * * page 14; example 1 * * page 16; example 2 *	1-3,8,9	
Y	SCHEHA M ET AL: "QUANTITATIVE MONITORING OF GENE EXPRESSION PATTERNS WITH A COMPLEMENTARY DNA MICROARRAY" SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, US, vol. 270, October 1995 (1995-10), pages 467-470, XP000644675 ISSN: 0036-8075 * page 467, right-hand column *	1,5	
Y	CHEUNG V G ET AL: "MAKING AND READING MICROARRAYS" NATURE GENETICS, NEW YORK, NY, US, vol. 21, January 1999 (1999-01), pages 15-19, XP002923682 ISSN: 1061-4036 * page 15, right-hand column *	1,5	TECHNICAL FIELDS SEARCHED (Int.Cl.7)
The present search report has been drawn up for all claims			
Place of search MUNICH		Date of completion of the search 19 September 2003	Examiner Leber, T
CATEGORY OF CITED DOCUMENTS X: particularly relevant if taken alone Y: particularly relevant if combined with another document of the same category A: technological background O: non-written disclosure P: intermediate document		T: theory or principle underlying the invention E: earlier patent document, but published on, or after the filing date D: document cited in the application L: document cited for other reasons &: member of the same patent family, corresponding document	

EPO FORM 1503 03 02 (P04001)



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 02 25 7873

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
D,Y	FROMMER M. ET AL.: "A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands" PROC. NATL. ACAD. SCI., vol. 89, March 1992 (1992-03), pages 1827-1831, XP002941272 * abstract * * page 1827, right-hand column - page 1828, left-hand column * * figure 1 *	8,9	TECHNICAL FIELDS SEARCHED (Int.Cl.7)
Y	HACIA J G: "RESEQUENCING AND MUTATIONAL ANALYSIS USING OLIGONUCLEOTIDE MICROARRAYS" NATURE GENETICS, NEW YORK, NY, US, vol. 21, no. SUPPL, January 1999 (1999-01), pages 42-47, XP000865986 ISSN: 1061-4036 * the whole document *	8,9	
Y	HUANG TIM HUI-MING ET AL: "Methylation profiling of CpG islands in human breast cancer cells" HUMAN MOLECULAR GENETICS, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 8, no. 3, March 1999 (1999-03), pages 459-470, XP002175857 ISSN: 0964-6906 * abstract * * page 461; figure 2 * * page 462; figure 4 * * the whole document *	8,9	
The present search report has been drawn up for all claims			
Place of search MUNICH		Date of completion of the search 19 September 2003	Examiner Leber, T
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document	

EPO FORM 1503 (01.02.02) (PUBO01)



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number

EP 02 25 7873

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
P,X	GITAN RAAD S ET AL: "Methylation-specific oligonucleotide microarray: a new potential for high-throughput methylation analysis" GENOME RESEARCH, COLD SPRING HARBOR LABORATORY PRESS, US, vol. 12, no. 1, January 2002 (2002-01), pages 158-164, XP002208051 ISSN: 1088-9051 * abstract * * page 163, left-hand column * * page 159; figures 1,2 * * page 162, right-hand column * * page 161; figure 4 *	1-9	
P,X	WD 02 077272 A (PIEPENBROCK CHRISTIAN ;ADORJAN PETER (DE); BERLIN KURT (DE); LESCH) 3 October 2002 (2002-10-03) * page 1, last paragraph - page 10, paragraph 2 * * page 18; example 1 *	1-4,6-9	
P,X	WD 02 18632 A (PIEPENBROCK CHRISTIAN ;BERLIN KURT (DE); EPIGENOMICS AG (DE); GUET) 7 March 2002 (2002-03-07) * page 14, line 22 - page 15, line 10 * * page 18, line 4 - line 11 * * page 33; example 1 * * page 35; example 3 *	1-4,6-9	TECHNICAL FIELDS SEARCHED (Int.Cl.7)
E	WD 02 103041 A (ADORJAN PETER ;DISTLER JUERGEN (DE); EPIGENOMICS AG (DE); MODEL FA) 27 December 2002 (2002-12-27) * page 9, paragraph 2 - page 11, paragraph 2 * * page 13; example 1 *	1-4,6-9	
The present search report has been drawn up for all claims			
Place of search MUNICH		Date of completion of the search 19 September 2003	Examiner Leber, T
<p>CATEGORY OF CITED DOCUMENTS</p> <p>X: particularly relevant if taken alone Y: particularly relevant if combined with another document of the same category A: technological background O: non-written disclosure P: intermediate document</p> <p>T: theory or principle underlying the invention E: earlier patent document, but published on, or after the filing date D: document cited in the application L: document cited for other reasons &: member of the same patent family, corresponding document</p>			

EPO FORM 1503 03.02 (P04001)

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 02 25 7873

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

19-09-2003

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 6214556	B1	10-04-2001	DE 19754482 A1	01-07-1999
			AT 217348 T	15-05-2002
			AU 753368 B2	17-10-2002
			AU 2408599 A	16-06-1999
			CA 2310384 A1	10-06-1999
			CN 1283235 T	07-02-2001
			WO 9928498 A2	10-06-1999
			DE 59804090 D1	13-06-2002
			DK 1034309 T3	26-08-2002
			EP 1034309 A2	13-09-2000
			ES 2173669 T3	16-10-2002
			HU 0100424 A2	28-06-2001
			JP 2001525181 T	11-12-2001
			NZ 504586 A	25-10-2002
			PL 341681 A1	23-04-2001
			PT 1034309 T	31-10-2002
			SI 1034309 T1	31-08-2002
DE 19853398	C	16-03-2000	DE 19853398 C1	16-03-2000
			AU 757473 B2	20-02-2003
			AU 1856500 A	13-06-2000
			CA 2351143 A1	02-06-2000
			WO 0031294 A2	02-06-2000
			EP 1135526 A2	26-09-2001
			JP 2002530118 T	17-09-2002
EP 1130121	A	05-09-2001	EP 1130121 A2	05-09-2001
			JP 2001281246 A	10-10-2001
			US 2002018996 A1	14-02-2002
DE 10013847	A	27-09-2001	DE 10013847 A1	27-09-2001
			AU 4835201 A	24-09-2001
			AU 5038101 A	24-09-2001
			AU 5460101 A	24-09-2001
			WO 0168910 A2	20-09-2001
			WO 0168911 A2	20-09-2001
			WO 0168912 A2	20-09-2001
			EP 1283905 A2	19-02-2003
			EP 1268855 A2	02-01-2003
			EP 1292707 A2	19-03-2003
WO 0176451	A	18-10-2001	DE 10019058 A1	20-12-2001
			DE 10032529 A1	07-02-2002
			AU 4835201 A	24-09-2001
			AU 5038101 A	24-09-2001
			AU 5478801 A	23-10-2001

EPO FORM P/0459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 02 25 7873

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

19-09-2003

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 0176451 A	AU	5479401 A	23-10-2001
	AU	7384001 A	23-10-2001
	AU	7566301 A	23-10-2001
	AU	7633001 A	23-10-2001
	AU	7633101 A	23-10-2001
	AU	7748701 A	23-10-2001
	AU	7842001 A	07-11-2001
	AU	8960001 A	11-12-2001
	WO	0177373 A2	18-10-2001
	WO	0168911 A2	20-09-2001
	WO	0168912 A2	20-09-2001
	WO	0177375 A2	18-10-2001
	WO	0177164 A2	18-10-2001
	WO	0177376 A2	18-10-2001
	WO	0177377 A2	18-10-2001
	WO	0181622 A2	01-11-2001
	WO	0192565 A2	06-12-2001
	WO	0177378 A2	18-10-2001
	WO	0176451 A2	18-10-2001
	EP	1283905 A2	19-02-2003
	EP	1268855 A2	02-01-2003
	EP	1268857 A2	02-01-2003
	EP	1272670 A2	08-01-2003
	EP	1278892 A1	29-01-2003
	EP	1278893 A2	29-01-2003
	EP	1274865 A2	15-01-2003
	EP	1274866 A2	15-01-2003
	EP	1268861 A2	02-01-2003
	US	2003082609 A1	01-05-2003
	US	2003162194 A1	28-08-2003
	US	2003148326 A1	07-08-2003
	US	2003148327 A1	07-08-2003
	AU	5057201 A	23-10-2001
	EP	1268856 A2	02-01-2003
	WO	0177384 A2	18-10-2001
	AU	7637101 A	14-01-2002
	AU	7752101 A	14-01-2002
	AU	7765301 A	08-01-2002
	AU	7970701 A	14-01-2002
	AU	8391501 A	08-01-2002
	AU	8391601 A	14-01-2002
	AU	8757501 A	08-01-2002
	AU	8757601 A	08-01-2002
	AU	8961701 A	08-01-2002
	WO	0202806 A2	10-01-2002

EPO FORM P0159

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 02 25 7873

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

19-09-2003

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
WO 02077272	A	03-10-2002	WO	02077895 A2	03-10-2002
			WO	02077272 A2	03-10-2002
			US	2002192686 A1	19-12-2002
<hr/>					
WO 0218632	A	07-03-2002	DE	10044543 A1	04-04-2002
			AU	1218702 A	13-03-2002
			AU	1218802 A	13-03-2002
			AU	4835201 A	24-09-2001
			AU	5038101 A	24-09-2001
			AU	5478801 A	23-10-2001
			AU	5479401 A	23-10-2001
			AU	7566301 A	23-10-2001
			AU	7633001 A	23-10-2001
			AU	7633101 A	23-10-2001
			AU	7637101 A	14-01-2002
			AU	7748701 A	23-10-2001
			AU	7752101 A	14-01-2002
			AU	7842001 A	07-11-2001
			AU	7970701 A	14-01-2002
			AU	8391501 A	08-01-2002
			AU	8391601 A	14-01-2002
			AU	8757501 A	08-01-2002
			AU	8757601 A	08-01-2002
			AU	8960001 A	11-12-2001
			AU	8961701 A	08-01-2002
			CA	2420840 A1	27-02-2003
			WO	0168911 A2	20-09-2001
			WO	0168912 A2	20-09-2001
			WO	0177375 A2	18-10-2001
			WO	0177164 A2	18-10-2001
			WO	0177376 A2	18-10-2001
			WO	0177377 A2	18-10-2001
			WO	0181622 A2	01-11-2001
			WO	0192565 A2	06-12-2001
			WO	0177378 A2	18-10-2001
			WO	0176451 A2	18-10-2001
			WO	0202806 A2	10-01-2002
			WO	0202807 A2	10-01-2002
			WO	0200926 A2	03-01-2002
			WO	0200927 A2	03-01-2002
			WO	0200928 A2	03-01-2002
			WO	0202808 A2	10-01-2002
			WO	0200705 A2	03-01-2002
			WO	0202809 A2	10-01-2002
			WO	0218631 A2	07-03-2002
			WO	0218632 A2	07-03-2002

EPO FORM P0459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 02 25 7873

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

19-09-2003

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 0218632 A		EP 1283905 A2	19-02-2003
		EP 1268855 A2	02-01-2003
		EP 1268857 A2	02-01-2003
		EP 1272670 A2	08-01-2003
		EP 1278893 A2	29-01-2003
		EP 1274865 A2	15-01-2003
		EP 1274866 A2	15-01-2003
		EP 1294947 A2	26-03-2003
WO 02103041 A	27-12-2002	DE 10128509 A1	02-01-2003
		WO 02103041 A2	27-12-2002

EPO FORM P0459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

This Page Blank (uspto)

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☒ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

This Page Blank (uspto)